RxDoctor Payments Data

Dermot Phelan, MD

Cardiovascular Disease · Charlotte, NCNPI 1750666186

Payments from drug & device makers

$146,739in general payments, 2019–2025

Across 59 payments — averaging $2487.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$131K
  • Pfizer$10K
  • Philips North America LLC$4K
  • Caption Health, Inc.$1K
  • Abbott$320
  • Siemens Medical Solutions USA, Inc.$184
  • plus $135 from 2 others
$18,600in research payments, 2019–2025

Across 2 payments — averaging $9300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Caption Health, Inc.$19K

What the payments were for

  • Consulting fees$17,68523%
  • Speaking & faculty fees$55,73373%
  • Travel & lodging$1,8132%
  • Food & beverage$9741%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,739 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$44,204
Medicare patients
314
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten27$237,483
EliquisApixaban47$57,526
JardianceEmpagliflozin22$19,152
Repatha SureclickEvolocumab24$18,459
Rosuvastatin Calcium29$2,206
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$668
Metoprolol Succinate33$578
Losartan Potassium22$190
Verapamil ErVerapamil Hcl13$167
Metoprolol Tartrate40$160
Amlodipine Besylate23$149
Atorvastatin Calcium22$97
Furosemide13$80
Carvedilol14$40
Spironolactone11$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$131,152$237,48327 claims
PfizerEliquis$9,613$57,52647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →